Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide/Formoterol Spiromax vs Symbicort Turbohaler in Persistent Asthma
NCT01803555Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2013
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of budesonide + formoterol in asthma (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow at 12 weeks. Started Jul 2013; status: completed.
02
Drugs
budesonide + formoterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01803555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01803555.